This issue of Endocrinology and Metabolism Clinics, edited by Dr. Ashley Grossman, will focus on Innovations in the Management of Neuroendocrine Tumors. Topics include, but are not limited to, Molecular targeted therapy of NETs – State of the art; Surgical approaches to the management of liver metastases; Liquid biopsies for NETs – circulating tumour cells and DNA; Novel functional imaging of NETs; The problem of appendiceal carcinoids; Peptide radioreceptor therapy comes of age; Current chemotherapy use in NETs; The problem of grade 3 NETs; Molecular genetic studies of pancreatic neuroendocrine tumours reveal new therapeutic approaches; The new WHO classification; Gastrinomas – medical or surgical treatment; When and how to use somatostatin analogues; The NETest as the way forward; Lung and thymic carcinoids; Carcinoid heart disease; Gastric carcinoids; New treatments for the carcinoid syndrome; and The genesis of the NETs concept – From Oberdorfer to 2018.

Hepato-Pancreato-Biliary cancers are increasing in incidence, with pancreatic cancer now accounting for the third most cancer deaths in the United States. Typically these malignancies, as a group, are managed by the same key providers comprising a multidisciplinary team. This book is intended to provide a comprehensive review of the current knowledge in the field of hepato-pancreato-biliary malignancies, focusing on the practical and clinical care of patients. We take the approach of combining the collective expertise of an interventional gastroenterologist and a hepato-pancreato-biliary surgeon to provide the readers with accurate, succinct, and pragmatic information needed to formulate the most appropriate treatment plan for their patients with the aim of the best possible outcome. Managing patients with these cancers continues to be challenging because of continued dismal survival rates. Each section in this text is written by experts in their respective field, summarizing the most state-of-the-art, contemporary diagnostic and therapeutic tools available in the field. We believe this book will prove to be an invaluable, comprehensive resource for all members of the multidisciplinary team caring for patients with hepato-pancreato-biliary malignancies.

The only in-depth source to focus specifically on surgical complications, this reference provides practical information on the incidence, management, and avoidance of complications encountered during and after surgical procedures. Spanning the vast array of complications related to a wide variety of preoperative, intraoperative, and postoperative e

Our understanding of pancreatic tumors is changing thanks to recent advances in the field. New diagnostic techniques and imaging tests have improved the early diagnosis of these lesions, and as a result, the growing number of R0 surgical resections has meant a better prognosis for patients. Further, minimally invasive laparoscopic approaches have increased postoperative comfort. Presenting the latest research in the field, this book will appeal to clinicians in a wide range of medical specialities, including gastroenterologists, general physicians, and abdominal and biliopancreatic surgeons.

Based on the experience gained by PET/CT experts with more than 10,000 patients, this manual impressively demonstrates the advantages of combined PET/CT. It also refers to publications from Europe, the USA and Asia as well as numerous studies.

Described as ‘must-have for cancer research’ by theHospital Doctor this highly acclaimed textbook has beenextensively revised and updated to reflect recent progress andunderstanding in the field. It is the only comprehensive source ofinformation available on uncommon cancers; presenting diagnosis,detailed clinical management and prognosis. The Textbook ofUncommon Cancer, Third Edition incorporated 18 newchapters, including: Tumors of the cervix Esthesioneuroblastoma Unusual malignancies of plasma cells Dermatofibrosarcoma protuberans Written by leading clinicians worldwide, this title isindispensable for all those involved in the diagnosis and treatmentof hard-to-manage rare tumors.